Skip to content

Trevi Therapeutics

US · TRVI #2810 by market cap Listed 2019
13.35 -0.37 -2.70%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

About Trevi Therapeutics

Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of Haduvio to treat neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough. The company was founded by Thomas R. Sciascia and Jennifer L. Good in 2011 and is headquartered in New Haven, CT.

Founded
2011
CEO
Ms. Jennifer L. Good
Employees
34
Headquarters
New Haven, Connecticut, United States of America
Fiscal year end
12-31
Website
trevitherapeutics.com

Company profile

Exchange
US
Symbol
TRVI
Market-cap rank
#2810
Listing date
2019-05-07
Market cap
1.90B
Float cap
1.59B
Shares out
142.56M
Float shares
118.81M

Sectors & themes

Browse all sectors & themes

Quote time 2026-11-20 20:02:43 · For reference only, not investment advice and not tailored to your situation.

Trevi Therapeutics discussion 0 comments

Add a comment